Yusuke Okuma (Y Okuma)

Scopus Author ID Researcher Name Resolver ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 34

Top Topics

Tyrosine Kinase

Liver Metastases

Myasthenia Gravis

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of cancer research and clinical oncology

Cancer immunology, immunotherapy : CII

This page only lists publications with an associated author ORCID identifier.

Publications

Akito Fukuda, Yusuke Okuma
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Akito Fukuda, Yusuke Okuma
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Akito Fukuda, Yusuke Okuma
From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Tomohiro Tanaka, Yasushi Goto, Masafumi Horie, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noriko Motoi, Yasushi Yatabe, Shunichi Watanabe, Noboru Yamamoto, Yuichiro Ohe
Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy. Cancers 15 (16) (2023)
Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Katsuhiko Naoki, Takaaki Tsuchida, Ryuji Hamamoto, Noboru Yamamoto, Noriko Motoi, Takashi Kohno, Shun-Ichi Watanabe, Yuichiro Ohe
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer. British journal of cancer (2023)
Masahiro Torasawa, Hidehito Horinouchi, Shigehiro Yagishita, Hirofumi Utsumi, Keitaro Okuda, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Saori Murata, Sawako Kaku, Kae Okuma, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Jun Araya, Yuichiro Ohe, Yu Fujita
Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles. Thoracic cancer (2023)
Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Naoko Goto, Shigehiro Yagishita, Tatsuya Imabayashi, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Katsuhiko Naoki, Takaaki Tsuchida, Ryuji Hamamoto, Noboru Yamamoto, Noriko Motoi, Takashi Kohno, Shun-Ichi Watanabe, Yuichiro Ohe
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer. British journal of cancer (2023)
Yusuke Okuma, Shogo Nomura, Kiichiro Ninomiya, Hiroshi Gyotoku, Shuji Murakami, Yoshihito Kogure, Daijiro Harada, Kyoichi Okishio, Hiroaki Okamoto, Yasushi Goto
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study). Future oncology (London, England) (2023)
Taiki Hakozaki, Alexis Nolin-Lapalme, Masato Kogawa, Yusuke Okuma, Shohei Nakamura, Danielle Moreau-Amaru, Taichi Tamura, Yukio Hosomi, Haruko Takeyama, Corentin Richard, Masahito Hosokawa, Bertrand Routy
Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis. Cancers 14 (21) (2022)
Yutaka Muto, Yusuke Okuma
Therapeutic options in thymomas and thymic carcinomas. Expert review of anticancer therapy 22 (4) (2022)
Tomoyasu Mimori, Takehito Shukuya, Ryo Ko, Yusuke Okuma, Tomonobu Koizumi, Hisao Imai, Yuichi Takiguchi, Eisaku Miyauchi, Hiroshi Kagamu, Tomohide Sugiyama, Keisuke Azuma, Yukiko Namba, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Kunihiko Kobayashi, Kazuhisa Takahashi
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. Cancers 14 (2) (2022)
Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, Hideaki Mizutani, Hiroshi Wakui, Shuji Murakami, Shinji Atagi, Koichi Minato, Masahiro Seike, Yuichiro Ohe, Kaoru Kubota, null null
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901). Future oncology (London, England) 18 (5) (2022)
Rui Kitadai, Yusuke Okuma
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers 14 (10) (2022)
Takashi Kohno, Mamoru Kato, Shinji Kohsaka, Tomohisa Sudo, Ikuo Tamai, Yuichi Shiraishi, Yusuke Okuma, Daisuke Ogasawara, Tatsuya Suzuki, Teruhiko Yoshida, Hiroyuki Mano
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan. Cancer discovery 12 (11) (2022)
Shigemasa Takamizawa, Yusuke Okuma, Yasuhiro Kato, Taiki Hakozaki, Shingo Kitagawa, Yoshitaka Zenke
First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status. Future oncology (London, England) (2021)
Rui Kitadai, Yusuke Okuma
Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma. Cancers 13 (20) (2021)
Hironori Satoh, Yusuke Okuma, Jumpei Kashima, Aya Konnno-Yamamoto, Yasushi Yatabe, Yuichiro Ohe
Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma. OncoTargets and therapy 14 (2021)
Makoto Nishio, Haruhiro Saito, Koichi Goto, Satoshi Watanabe, Naoko Sueoka-Aragane, Yusuke Okuma, Kazuo Kasahara, Kenichi Chikamori, Yuki Nakagawa, Tomohisa Kawakami
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients. Cancer science 112 (4) (2021)
Hiroshi Takumida, Hidehito Horinouchi, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Yuichiro Ohe
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. Cancer immunology, immunotherapy : CII (2021)
Fyza Y Shaikh, James R White, Joell J Gills, Taiki Hakozaki, Corentin Richard, Bertrand Routy, Yusuke Okuma, Mykhaylo Usyk, Abhishek Pandey, Jeffrey S Weber, Jiyoung Ahn, Evan J Lipson, Jarushka Naidoo, Drew M Pardoll, Cynthia L Sears
A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (9) (2021)
Kageaki Watanabe, Yusuke Okuma, Shoko Kawai, Makoto Nagamata, Yukio Hosomi
Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma. Thoracic cancer 12 (11) (2021)
Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, Kuniko Sunami, Yoshiro Nakahara, Satoru Kitazono, Keita Kudo, Yuichi Tambo, Shintaro Kanda, Noriko Yanagitani, Atsushi Horiike, Hidehito Horinouchi, Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Makoto Nishio, Yuichiro Ohe, Yukio Hosomi
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma. Cancer medicine 9 (20) (2020)
Taiki Hakozaki, Corentin Richard, Arielle Elkrief, Yukio Hosomi, Myriam Benlaïfaoui, Iris Mimpen, Safae Terrisse, Lisa Derosa, Laurence Zitvogel, Bertrand Routy, Yusuke Okuma
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer. Cancer immunology research 8 (10) (2020)
Jumpei Kashima, Rui Kitadai, Yusuke Okuma
Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. Cancers 11 (5) (2019)
Rui Kitadai, Yusuke Okuma, Taiki Hakozaki, Yukio Hosomi
The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. Journal of cancer research and clinical oncology 146 (3) (2019)
Taiki Hakozaki, Yusuke Okuma, Kana Hashimoto, Yukio Hosomi
Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis. Journal of cancer research and clinical oncology 145 (10) (2019)
Yusuke Okuma, Kei Morikawa, Hisashi Tanaka, Takuma Yokoyama, Hidetoshi Itani, Kazuya Horiuchi, Hideyuki Nakagawa, Nobumasa Takahashi, Akihiro Bessho, Kenzo Soejima, Kazuma Kishi, Akira Togashi, Yae Kanai, Koji Ueda, Katsuhisa Horimoto, Noriyuki Matsutani, Nobuhiko Seki
Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study). Thoracic cancer 10 (2) (2018)
Yusuke Okuma, Jumpei Kashima, Kageaki Watanabe, Sadamu Homma
Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. Journal of cancer research and clinical oncology 144 (8) (2018)
Taiki Hakozaki, Yusuke Okuma, Jumpei Kashima
Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. BMC cancer 18 (1) (2018)
A Mitsuhashi, Yusuke Okuma
Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20 (8) (2018)
Jumpei Kashima, Yusuke Okuma
Response to "Immune-mediated cholangitis: is it always nivolumab's fault?" Cancer immunology, immunotherapy : CII 67 (8) (2018)
Yusuke Okuma, Tsunekazu Hishima, Jumpei Kashima, Sadamu Homma
High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. Cancer immunology, immunotherapy : CII 67 (3) (2017)
Yusuke Okuma, Yukio Hosomi, Satoshi Takahashi, Yoshiro Nakahara, Kageaki Watanabe, Makoto Nagamata, Yusuke Takagi, Shinichiro Mikura
A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology 78 (2) (2016)
Kana Hashimoto, Yusuke Okuma, Yukio Hosomi, Tsunekazu Hishima
Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review. BMC cancer 16 (2016)
Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe, Satoshi Takahashi, Tatsuru Okamura, Tsunekazu Hishima
Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations. International journal of clinical oncology 21 (3) (2015)